Small intestine neuroendocrine tumour

Pharmaceutical company Ipsen has reported positive results from a phase III controlled study of lanreotide antiproliferative response in neuroendocrine tumours (CLARINET) of Somatuline Autogel 120mg in gastrointestinal and pancreatic neuroendocrine tumours (GEP-NETs).

Treatment with Somatuline Autogel 120mg demonstrated statistically significant improvement in progression-free survival compared to a placebo with a consistent safety profile to that of Somatuline.

The first large-scale, placebo-controlled, randomised CLARINET study demonstrated the anti-tumoral activity of a somatostatin analogue in non-functioning GEP-NETs.

CLARINET principal investigator and Royal Free Hospital gastroenterology and gastrointestinal neuroendocrinology professor Dr Martyn Caplin said that this first study inclusive of GEP-NETs provides clear evidence that Somatuline Autogel 120mg delays tumour progression or death.

"These important results will help the medical community to confirm the place of Somatuline Autogel in the treatment algorithm of these patients," he said.

Ipsen chief scientific officer and Research & Development executive vice-president Claude Bertrand said: "We believe it should meet the expectations of physicians by potentially providing a new treatment option for patients with gastrointestinal and pancreatic neuroendocrine tumours."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The multinational study conducted two baseline computed tomography scans, followed by additional scans at intervals up to 96 weeks.

Image: High magnification micrograph of a small intestine neuroendocrine tumour. H&E stain. Photo: Nephron.